PL-23 measurement of the new anticoagulants

Thrombosis Research

Volumn 129, Issue SUPPL. 1, 2012, Pages

  Harenberg, Job ^a   Kraemer, Roland ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Dabigatran; Factor Xa inhibitors; Oral anticoagulants; POCT (Point of care Testing); Rivaroxaban; Thrombin inhibitors; Urine test

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; CREATININE; DABIGATRAN; RIVAROXABAN; THROMBIN INHIBITOR;

BLOOD CLOTTING TIME; BLOOD SAMPLING; CONFERENCE PAPER; CREATININE CLEARANCE; HEART ATRIUM FIBRILLATION; HIP ARTHROPLASTY; PATIENT CARE; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTHROMBIN TIME; TOTAL KNEE REPLACEMENT; URINALYSIS; VENOUS THROMBOEMBOLISM; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; DRUG EFFECT; HUMAN; METHODOLOGY; URINE;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; HUMANS; VENOUS THROMBOEMBOLISM;

EID: 84862122095     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(12)70028-2     Document Type: Conference Paper

References (67)

1. WH Geerts, D Bergqvist, GF Pineo, JA Heit, CM Samama, MR Lassen et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 2008 381S 453S (Pubitemid 351894916)
2. J Hirsh, KA Bauer, MB Donati, M Gould, MM Samama, JI Weitz Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 2008 141S 159S (Pubitemid 351892966)
3. J Ansell, J Hirsh, E Hylek, A Jacobson, M Crowther, G Palareti Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 2008 160S 198S (Pubitemid 351892967)
4. C Kearon, SR Kahn, G Agnelli, S Goldhaber, GE Raskob, AJ Comerota Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 2008 454S 545S (Pubitemid 351892971)
5. DE Singer, GW Albers, JE Dalen, MC Fang, AS Go, JL Halperin et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 2008 546S 592S (Pubitemid 351892972)
6. RC Becker, TW Meade, PB Berger, M Ezekowitz, CM O'Connor, DA Vorchheimer et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 2008 776S 814S (Pubitemid 351894917)
7. JL Mega, E Braunwald, SD Wiviott, JP Bassand, DL Bhatt, C Bode et al. Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
8. TE Warkentin, A Greinacher, A Koster, AM Lincoff Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 340S 380S (Pubitemid 351892970)
9. WL Baker, DA Cios, SD Sander, CI Coleman Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States J Manag Care Pharm 15 2009 244 252
10. J Harenberg, S Marx, M Krejczy, M Wehling New anticoagulants - promising and failed developments Br J Pharmacol 165 2012 363 372
11. JB Olesen, GY Lip, J Lindhardsen, DA Lane, O Ahlehoff, ML Hansen et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study Thromb Haemost 106 2011 739 749
12. IM Ogilvie, N Newton, SA Welner, W Cowell, GY Lip Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med 123 2010 638 645
13. CH Moore, J Snashall, K Boniface, J Scott Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation Am J Emerg Med 2011
14. Bleeding with dabigatran (Pradaxa) Med Lett Drugs Ther 53 2011 98
15. I Casado Naranjo, JC Portilla-Cuenca, PE Jimenez Caballero, ML Calle Escobar, RM Romero Sevilla Fatal Intracerebral Hemorrhage Associated with Administration of Recombinant Tissue Plasminogen Activator in a Stroke Patient on Treatment with Dabigatran Cerebrovasc Dis 32 2011 614 615
16. JL Anderson, CD Adams, EM Antman, CR Bridges, RM Califf, DE Casey Jr. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J Am Coll Cardiol 50 2007 e1 e157
17. Y Tomonaga, F Gutzwiller, TF Luscher, WF Riesen, M Hug, A Diemand et al. Diagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trial BMC Fam Pract 12 2011 12
18. JJ Sidelmann, J Gram, A Larsen, K Overgaard, J Jespersen Analytical and clinical validation of a new point-of-care testing system for determination of D-Dimer in human blood Thromb Res 126 2010 524 530
19. EM Van Cott Point-of-care testing in coagulation Clin Lab Med 29 2009 543 553
20. J Jespersen, L Poller, AM van den Besselaar, FJ van der Meer, G Palareti, A Tripodi et al. External quality assessment (EQA) for CoaguChek monitors Thromb Haemost 103 2010 936 941
21. F Chen, V Maridakis, EA O'Neill, C Beals, W Radziszewski, I de Lepeleire et al. A randomized clinical trial comparing point-of-care platelet function assays and bleeding time in healthy subjects treated with aspirin or clopidogrel Platelets 2011
22. K Gorlinger, D Dirkmann, AA Hanke, M Kamler, E Kottenberg, M Thielmann et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study Anesthesiology 115 2011 1179 1191
23. MM Samama, JL Martinoli, L LeFlem, C Guinet, G Plu-Bureau, F Depasse et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor Thromb Haemost 103 2010 815 825
24. L Baruch, O Sherman Potential inaccuracy of point-of-care INR in dabigatran-treated patients Ann Pharmacother 45 2011 e40
25. CE DeRemer, JS Gujral, JW Thornton, RA Sorrentino Dabigatran falsely elevates point of care international normalized ratio results Am J Med 124 2011 e5 e6
26. J Harenberg, S Marx, R Kramer, C Giese, C Weiss Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban Blood Coagul Fibrinolysis 2011
27. A Tripodi, V Chantarangkul, C Guinet, MM Samama The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study J Thromb Haemost 9 2011 226 228
28. J Harenberg, C Giese, S Marx, R Kraemer Determination of rivaroxaban in human plasma samples Semin Thromb Hemost 2012
29. TL Lindahl, F Baghaei, IF Blixter, KM Gustafsson, L Stigendal, M Sten-Linder et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays Thromb Haemost 105 2011 371 378
30. J Harenberg, C Giese, S Marx, R Kraemer Determination of Dabigatran in Human Plasma Samples Semin Thromb Hemost 38 2012 16 22
31. J Harenberg, C Giese, A Hagedorn, I Traeger, T Fenyvesi Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time Semin Thromb Hemost 33 2007 503 507 (Pubitemid 47105740)
32. S Harder, J Parisius, B Picard-Willems Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications Thromb Res 123 2008 396 403
33. J Harenberg, S Marx, C Giese Determination of the anticoagulant effects of new oral anticoagulants - an unmet need Expert Review Haematology 2012 V
34. J van Ryn, J Stangier, S Haertter, KH Liesenfeld, W Wienen, M Feuring et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
35. F Kornalik, B Blomback Prothrombin activation induced by Ecarin - a prothrombin converting enzyme from Echis carinatus venom Thromb Res 6 1975 57 63
36. G Nowak, E Bucha Quantitative determination of hirudin in blood and body fluids Semin Thromb Hemost 22 1996 197 202 (Pubitemid 26239913)
37. T Fenyvesi, J Harenberg, C Weiss, I Jorg Comparison of two different ecarin clotting time methods J Thromb Thrombolysis 20 2005 51 56 (Pubitemid 41300623)
38. J Harenberg, R Kramer, C Giese, S Marx, C Weiss, M Wehling Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability J Thromb Thrombolysis 32 2011 267 271
39. U Lange, G Nowak, E Bucha Ecarin chromogenic assay - a new method for quantitative determination of direct thrombin inhibitors like hirudin Pathophysiol Haemost Thromb 33 2003 184 191 (Pubitemid 39664136)
40. LM Asmis, L Alberio, A Angelillo-Scherrer, W Korte, A Mendez, G Reber et al. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories Thromb Res 2011
41. MM Samama, G Contant, TE Spiro, E Perzborn, C Guinet, Y Gourmelin et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls Thromb Haemost 2012
42. J Harenberg, S Marx, C Weiss, R Kraemer, M Samama, S Schulman Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban J Thromb Haemost 2012
43. C Mahler, K Hermann, R Horne, S Ludt, WE Haefeli, J Szecsenyi et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany J Eval Clin Pract 16 2010 574 579
44. ME Attema-de Jonge, SY Peeters, EJ Franssen Performance of Three Point-of-care Urinalysis Test Devices for Drugs of Abuse and Therapeutic Drugs Applied in the Emergency Department J Emerg Med 2011
45. MA Cervinski, CM Lockwood, AM Ferguson, RR Odem, UH Stenman, H Alfthan et al. Qualitative point-of-care and over-the-counter urine hCG devices differentially detect the hCG variants of early pregnancy Clin Chim Acta 406 2009 81 85
46. Harenberg J, Kraemer R. Direct thrombin inhibitors, British Patent Application No GB1110502.0, 2011.
47. Harenberg J, Kraemer R. Direct factor Xa inhibitors, International Patent Application PCT/EP2011/005586, 2011.
48. Diet, nutrition and the prevention of chronic diseases World Health Organ Tech Rep Ser 916 2003 i viii 1-149, backcover.
49. JA Cramer A systematic review of adherence with medications for diabetes Diabetes Care 27 2004 1218 1224 (Pubitemid 38579798)
50. MA Huser, TS Evans, V Berger Medication adherence trends with statins Adv Ther 22 2005 163 171 (Pubitemid 40874910)
51. PV Burkhart, E Sabate Adherence to long-term therapies: evidence for action J Nurs Scholarsh 35 2003 207 (Pubitemid 38591659)
52. Horne R, Weinmann J, Barber N. Concordance, adherence and compliance in medicine taking. National Co-ordinating Centre for NHS Service Delivery and Organisation Research and Development: 2005.
53. JS Tabrizi, AJ Wilson, ET Coyne, PK O'Rourke Clients' perspective on service quality for type 2 diabetes in Australia Aust N Z J Public Health 31 2007 511 515
54. SH Kaplan, S Greenfield, JE Ware Jr Assessing the effects of physician-patient interactions on the outcomes of chronic disease Med Care 27 1989 S110 S127
55. BC Delaney, CJ Hyde, RJ McManus, S Wilson, DA Fitzmaurice, S Jowett et al. Systematic review of near patient test evaluations in primary care BMJ 319 1999 824 827 (Pubitemid 29445922)
56. DB Sacks, M Arnold, GL Bakris, DE Bruns, AR Horvath, MS Kirkman et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus Clin Chem 57 2011 e1 e47
57. SD Lawn, AD Kerkhoff, M Vogt, R Wood Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study Lancet Infect Dis 2011
58. S Wang, X Zhao, I Khimji, R Akbas, W Qiu, D Edwards et al. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care Lab Chip 11 2011 3411 3418
59. BH McCarberg A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management Postgrad Med 123 2011 124 131
60. LC Borris, M Breindahl, MR Lassen, AF Pap, F Misselwitz Differences in urinary prothrombin fragment 1 + 2 levels after total hip replacement in relation to venous thromboembolism and bleeding events J Thromb Haemost 6 2008 1671 1679
61. J Dunbar-Jacob, JA Erlen, EA Schlenk, CM Ryan, SM Sereika, WM Doswell Adherence in chronic disease Annu Rev Nurs Res 18 2000 48 90
62. C Heneghan, P Alonso-Coello, JM Garcia-Alamino, R Perera, E Meats, P Glasziou Self-monitoring of oral anticoagulation: a systematic review and meta-analysis Lancet 367 2006 404 411 (Pubitemid 43184260)
63. HE Bloomfield, A Krause, N Greer, BC Taylor, R MacDonald, I Rutks et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes Ann Intern Med 154 2011 472 482
64. JC Matthews, WS Wassif Potential risk of patient misclassification using a point-of-care testing kit for urine drugs of abuse Br J Biomed Sci 67 2010 218 220
65. G Lippi, EJ Favaloro, M Franchini Laboratory diagnostics and therapy in thrombosis and hemostasis: from bedside to bench to bedside Semin Thromb Hemost 35 2009 3 8
66. GC Guidi, G Lippi Will "personalized medicine" need personalized laboratory approach? Clin Chim Acta 400 2009 25 29
67. EJ Favaloro, G Lippi Coagulation update: what's new in hemostasis testing? Thromb Res 127 Suppl 2 2011 S13 S16